Showing Results for
- Academic Journals (51)
Search Results
- 51
Academic Journals
- 51
-
From:Psychiatric Times (Vol. 37, Issue 3) Peer-ReviewedPatient nonadherence to long-term antipsychotic therapy presents clinicians with unique unmet needs but also opportunities for promoting the realistic benefits of consistent treatment. According to the World Health...
-
From:Journal of Psychiatry and Neuroscience (Vol. 45, Issue 4) Peer-ReviewedA man in his 50s with schizophrenia was admitted involuntarily with a severe psychotic exacerbation. He had been stable for years on long-acting injectable antipsychotic medication. The inpatient psychiatrist reviewed...
-
From:CNS Drugs (Vol. 25, Issue 10) Peer-ReviewedPaliperidone palmitate is a second-generation, long-acting injectable (LAI) antipsychotic recently approved by the US FDA and European Medicines Agency for use in patients with schizophrenia. This article reviews the...
-
From:Drugs (Vol. 70, Issue 10) Peer-ReviewedPaliperidone, the major active metabolite of the atypical antipsychotic risperidone, is available in an oral extended-release (ER) formulation (Invega[R]) and is indicated for the acute and maintenance treatment of...
-
From:The Brown University Psychopharmacology Update (Vol. 32, Issue 5)* The effects of long-acting injectable (LAI) paliperidone on clinical and functional outcomes in patients with schizophrenia were compared in three patient groups classified by duration of illness. * All groups showed...
-
From:Archives of Neuropsychiatry (Vol. 57, Issue 3) Peer-ReviewedFahr's disease is a rare neurological disorder that is characterized by bilateral basal ganglia calcification. In the present study, a 49-year-old male patient presented with delusional beliefs. He had normal neurologic...
-
From:Psychiatric Times (Vol. 37, Issue 12) Peer-ReviewedSix-Month LAI for Schizophrenia in the Works Janssen Pharmaceutical Companies of Johnson & Johnson announced their supplemental New Drug Application (sNDA) submission for paliperidone palmitate 6-month (PP6M). If...
-
From:Psychiatric Times (Vol. 38, Issue 8) Peer-ReviewedAlthough psychosis often emerges relatively early in life, it can also appear for the first time in older patients. These cases raise special challenges. The morbidity and mortality rates for psychosis in late life are...
-
From:Reactions Weekly (Issue 1318)A 38-year-old woman developed hyperprolactinaemia while receiving paliperidone for schizophrenia. She started receiving paliperidone 9 mg/day while enrolled in an open-label trial. While receiving the agent over a...
-
From:The Brown University Psychopharmacology Update (Vol. 32, Issue 3)In my last commentary, for the January 2021 issue, (1) I took a look at the American Psychiatric Association's new practice guideline for the treatment of schizophrenia and suggested that even the "truisms" contained in...
-
From:Reactions Weekly (Issue 1320)Four patients developed hyperprolactinaemia during treatment with paliperidone. Patient 1, a 30-year-old woman, received paliperidone for schizophreniform psychosis; her initial dosage was 3 mg daily, which was...
-
From:Reactions Weekly (Issue 1338)[S] A 33-year-old woman with a 1-year history of hallucinations, delusions, aggression and unstable mood started treatment with paliperidone 6 mg/day [route not stated]. Her visual and auditory hallucinations...
-
From:The Brown University Psychopharmacology Update (Vol. 32, Issue 7)Clozapine is used in the management of treatment-resistant schizophrenia. However, its utility is limited by the occurrence of agranulocytosis, neutropenia, and leukopenia in up to 3% of patients, (1) necessitating...
-
From:Journal of Medical Sciences (Vol. 41, Issue 1) Peer-ReviewedByline: Cian-Cian. Lin, Tzu-Yun. Wang, Chuan-Chia. Chang, Nian-Sheng. Tzeng We report a case of a patient with schizophrenia-like disorder related to the right-side frontal lobe meningioma and oral cancer. This...
-
From:The Brown University Psychopharmacology Update (Vol. 30, Issue 1)A meta-analysis examined randomized controlled trials of at least 3 months in duration to compare relative risk of tardive dyskinesia (TD) between first- and second-generation antipsychotics. * The estimated TD risk...
-
From:Archives of Women's Mental Health (Vol. 21, Issue 6) Peer-ReviewedSchizophrenic or schizoaffective disorders often occur in early adulthood and thus affect women of childbearing age. For paliperidone information about reproductive safety is wanting. Therefore, we evaluated data from...
-
From:PLoS ONE (Vol. 12, Issue 8) Peer-ReviewedSchizophrenia is a chronic disease with negative impact on patients' employment status and quality of life. This post-hoc analysis uses data from the QUALIFY study to elucidate the relationship between work readiness...
-
From:PharmacoEconomics and Outcomes News (Vol. 607)Compared with other antipsychotic treatments, paliperidone prevents more relapses in patients with schizophrenia and appears to be potentially cost saving to the US payer, according to researchers affiliated with...
-
From:Psychiatric Times (Vol. 37, Issue 6) Peer-ReviewedThe complexity of addressing and avoiding drug interactions has become more challenging with the vast increase in the number of new medications and the shift in focus from time-limited acute treatments to preventive and...